Clinical Outcomes Research
Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data.
Our data warehouse is the largest in the outpatient infusion industry
Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence. The strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research.
Clinical Outcomes
Cost Savings & Lower Resource Utilization
New Therapies and Programs
Persistance
Special Populations
Here is an example of one of our class-leading studies enabled by our data:
Click image to view full size
Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX View Poster
All Categories
Evaluation of Fecal Microbiota, Live-jslm by Standard of Care Antibiotic Washout Period for the Prevention of Recurrent Clostridioides difficile Infection
Evaluation of Fecal Microbiota, Live-jslm by Standard of Care Antibiotic Washout Period for the Prevention of Recurrent Clostridioides difficile Infection
Presented at ACG 2025 Authors: Timothy E. Ritter, MD Jonathan A. Rosenberg, MD Richard L. Hengel MD Sujatha Krishan, MD Kathy A. Baker Ph.D., APRN Lucinda J. Van Anglen, PharmD Kelly E. Hanna, PharmD Mielad Moosapanah, PharmD Sanghyuk Seo, PharmD, MS Kevin W....
Efficacy and Safety of Rezafungin, A Long-Acting Echinocandin
Efficacy and Safety of Rezafungin, A Long-Acting Echinocandin
Presented at IDWeek 2025 Authors: Richard L. Hengel, MD, FIDSA Brian Metzger, MD, MPH Erika M. Young, DO Kent J. Stock, DO Joseph F. John, Jr., MD, FACP, FIDSA Kimberly A. Couch, PharmD, MA, FIDSA Christina Weeks, PharmD Lucinda J. Van Anglen, BS, PharmD, FIDSA...
Real-World Effectiveness and Health-Related Quality of Life Improvements Using Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection
Real-World Effectiveness and Health-Related Quality of Life Improvements Using Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection
Presented at IDWeek 2025 Authors: Richard L. Hengel MD Sujatha Krishan, MD Timothy E. Ritter, MD Jonathan A. Rosenberg, MD Kathy A. Baker Ph.D., APRN Lucinda J. Van Anglen, PharmD Kelly E. Hanna, PharmD Mielad Moosapanah, PharmD Sanghyuk Seo, PharmD, MS Kevin W....
Long-term Effectiveness of Long-Acting Cabotegravir and Rilpivirine in an Infectious Disease Office-Based HIV Program
Long-term Effectiveness of Long-Acting Cabotegravir and Rilpivirine in an Infectious Disease Office-Based HIV Program
Presented at IDWeek 2025 Authors: Nikhil K. Bhayani, MD, FIDSA Jorge R. Bernett, MD Thomas K. Sleweon, MD Erika M. Young, DO Kent J. Stock, DO Stacey E. Baker, MD Quyen Luu, MD Brian S. Metzger, MD, MPH Kimberly A. Couch, PharmD, MA, FIDSA, FASHP Christina J....
Real-World Experience with Rezafungin: A Novel Long-Acting Echinocandin
Real-World Experience with Rezafungin: A Novel Long-Acting Echinocandin
Presented at ESCMID Global 2025 The Healix Research Team was honored to showcase our latest collaborative study with our esteemed physician partners and Melinta Therapeutics at #ESCMIDGlobal, the prestigious Congress of the European Society of Clinical Microbiology...
Immune Globulin Subcutaneous 16.5% in Immunoglobulin-Naïve Patients with Primary Immunodeficiency
Immune Globulin Subcutaneous 16.5% in Immunoglobulin-Naïve Patients with Primary Immunodeficiency
Presented at AAAAI 2025 The Healix Research Team was proud to present in a collaborative outcomes research poster presentation with our esteemed physician partners at the American Academy of Allergy, Asthma and Immunology - AAAAI 2025 Annual Meeting on Saturday,...
Real-world Effectiveness and Onset of Action of Vedolizumab as a First-line Biologic in Biologic-Naïve Patients With Ulcerative Colitis
Real-world Effectiveness and Onset of Action of Vedolizumab as a First-line Biologic in Biologic-Naïve Patients With Ulcerative Colitis
Presented at ACG 2024 Authors: Precious A Anyanwu Lucinda J Van Anglen Chiahung Chou Marie Sanchirico Timothy E Ritter View Poster View...
Effectiveness of A Community-based Inflammatory Bowel Disease Medical Home Compared to Patients not in a Medical Home
Effectiveness of A Community-based Inflammatory Bowel Disease Medical Home Compared to Patients not in a Medical Home
Presented at ACG 2024 Authors: Erica Cohen, MD Timothy E. Ritter, MD Lucinda J. Van Anglen, BS, PharmD Fiza Z. Baloch Kristen Attiogbe Precious Anyanwu, PharmD, PhD Brooke Hodnick Justin G. Kweit, BS Tyler Varisco, PharmD, PhD View Poster View...
Immune Globulin Subcutaneous 16.5% in Treatment of Primary Immunodeficiency: A Two-Year, Multi-Center Analysis
Immune Globulin Subcutaneous 16.5% in Treatment of Primary Immunodeficiency: A Two-Year, Multi-Center Analysis
Presented at IgNS 2024 Authors: Lucinda J. Van Anglen, PharmD Miren Patel, PharmD Christina J. Weeks, PharmD Richard F. Herrscher, MD, FACAAI Jeffrey W. Langford, MD, AE-C Precious A. Anyanwu, PharmD, PhD View...
Telavancin Outcomes in Infections Treated with Outpatient Parenteral Antibiotic Therapy (OPAT)
Telavancin Outcomes in Infections Treated with Outpatient Parenteral Antibiotic Therapy (OPAT)
Presented at IDWeek 2024 Authors: Brian S. Metzger, MD, MPH Nikhil Bhayani, MD,FIDSA Thomas K. Sleweon, MD Rishi Bhattacharyya, MD Richard L. Hengel MD Kimberly A. Couch, PharmD Theresa L. Human, PharmD Emily A. Durr, PharmD Jason M. Makii, PharmD Lucinda J. Van...
Optimal Vancomycin Model Selection for Obese Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT)
Optimal Vancomycin Model Selection for Obese Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT)
Presented at IDWeek 2024 Authors: Kimberly A. Couch, PharmD, MA, FIDSA, FASHP Quyen Luu, MD Richard C. Prokesch, MD, FACP, FIDSA John S. Adams, MD, FIDSA, FSHEA Joseph F. John, Jr., MD, FACP, FIDSA Lucinda J. Van Anglen, BS, PharmD, FIDSA View...
Real-World Effectiveness of Fecal Microbiota, live-jslm for the Prevention of Recurrent Clostridioides difficile Infection
Real-World Effectiveness of Fecal Microbiota, live-jslm for the Prevention of Recurrent Clostridioides difficile Infection
Presented at IDWeek 2024 Authors: Richard L. Hengel, MD Sujatha Krishan, MD Timothy E. Ritter, MD Jonathan A. Rosenberg, MD Kathy A. Baker Ph.D., APRN Lucinda J. Van Anglen, PharmD Kelly E. Hanna, PharmD Amy Guo, PhD Mielad Moosapanah, PharmD Sanghyuk Seo, PharmD,...
Phase II and Phase III Studies
Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.
For information on partnering with Healix on a study, please contact us.